Claims

1. (Previously presented) A method of inhibiting endothelial cell growth, comprising:

contacting an endothelial cell with a polypeptide comprising an amino acid sequence at least 90% homologous to an amino acid sequence as set forth in SEQ ID NO: 2, or a therapeutically effective fragment thereof,

thereby inhibiting endothelial cell growth.

E1

2. (Previously presented) The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6.

D2

3. (Previously presented) The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 8.

4. (Previously presented) The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 5.

5. (Previously presented) A method of inhibiting angiogenesis in a subject, comprising:

administering to the subject a composition comprising a polypeptide comprising an amino acid sequence at least 90% homologous to an amino acid sequence as set forth in SEQ ID NO: 2, or a therapeutically effective fragment thereof,

thereby inhibiting angiogenesis in the subject.

6. (Previously presented) The method of claim 5, wherein the composition further comprises a pharmaceutically acceptable carrier.

7. (Previously presented) The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6.

8. (Previously presented) The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 8.

9-12. (Canceled)

13. (Previously presented) The method of claim 5, further comprising administering an anti-angiogenic agent comprising platelet-factor-4, IP-10 (interferon (IFN)-γ inducible protein-10), MIG (Monokine induced by IFN-γ), INF-γ, IFN-α, angiostatin, endostatin, fumagillin, AGM-1470, thrombospondin, a fragment of prolactin, antibody against the integrin $\alpha_v\beta_3$, IL-12, cleaved conformation of the serpin antithrombin, thalidomide, or a mixture thereof.

E1

14. (Previously presented) The method of claim 5, further comprising administering a chemotherapeutic agent.

D1/2

15. (Previously presented) The method of claim 5, further comprising administering a hormone.

16. (Previously presented) The method of claim 5, further comprising administering an anti-inflammatory agent.

17. (Previously presented) The method of claim 5, further comprising administering an anti-viral agent.

18-19. (Canceled)

20. (Previously presented) The method of claim 5, wherein the subject has periodontal disease.

21. (Previously presented) The method of claim 20, further comprising administering an antibiotic.

22. (Previously presented) The method of claim 5, wherein the subject has a radiation induced injury.

23. (Previously presented) The method of claim 5, wherein the subject has a chemotherapy induced injury.

24. (Previously presented) The method of claim 5, wherein the composition inhibits angiogenesis, wherein angiogenesis is stimulated in the subject by an angiogenesis inducer comprising basic fibroblast growth factor, acidic fibroblast growth factor, Vascular Endothelial Growth Factor (VEGF), hepatocyte growth factor, Interleukin (IL)-15, IL-8, platelet-derived endothelial cell growth factor (PDECGF), Transforming Growth Factor (TGF)-β, Tumor necrosis Factor (TNF)α, angiogenin, cripto, or a mixture thereof.

25. (Original) The method of claim 5, wherein the subject is immunocompromized due to T-lymphocyte deficiency.

26-56. (Canceled)

57. (Previously presented) The method of claim 1, wherein the therapeutically effective fragment of calreticulin consists essentially of:

(a) an amino acid sequence as set forth in SEQ ID NO: 5;

(b) an amino acid sequence as set forth in SEQ ID NO: 6;

(c) an amino acid sequence as set forth in SEQ ID NO: 8;

(d) an amino acid sequence as set forth in SEQ ID NO: 9; or

(e) an amino acid sequence as set forth in SEQ ID NO: 4.

58-59. (Canceled)

60. (Previously presented) The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 4.

61. (Previously presented) The method of claim 1, wherein the therapeutically effective fragment comprises SEQ ID NO: 9.

62. (Previously presented) The method of claim 1, wherein the polypeptide comprises an amino acid sequence at least 95% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

63. (Previously presented) The method of claim 62, wherein the polypeptide comprises an amino acid sequence at least 98% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

64. (Previously presented) The method of claim 63, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2.

65. (Previously presented) The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 5.

66. (Previously presented) The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 4.

67. (Previously presented) The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 9.

68. (Previously presented) The method of claim 5, wherein the polypeptide comprises an amino acid sequence at least 95% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

69. (Previously presented) The method of claim 68, wherein the polypeptide comprises an amino acid sequence at least 98% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

70. (Previously presented) The method of claim 69, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2.

71-76. (Canceled)

77. (Previously presented) The method of claim 5, wherein the subject has Kaposi sarcoma.

78. (Previously presented) The method of claim 1, wherein the endothelial cell is *in vitro*.

79. (Previously presented) The method of claim 1, wherein the endothelial cell is *in vivo*.

80. (New) The method of claim 1, wherein the endothelial cell is in a tumor in a subject.

81. (New) The method of claim 5, wherein the subject has a tumor.